Pir51, a Rad51-interacting protein with high expression in aggressive lymphoma, controls mitomycin C sensitivity and prevents chromosomal breaks
- 10 October 2006
- journal article
- Published by Elsevier in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
- Vol. 601 (1-2) , 113-124
- https://doi.org/10.1016/j.mrfmmm.2006.06.016
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Laboratory variability does not preclude identification of biological functions impacted by hydroxyureaEnvironmental and Molecular Mutagenesis, 2005
- Gene regulation profile reveals consistent anticancer properties of progesterone in hormone-independent breast cancer cells transfected with progesterone receptorInternational Journal of Cancer, 2005
- Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profileGenes, Chromosomes and Cancer, 2005
- BRCA2 Is Ubiquitinated In Vivo and Interacts with USP11, a Deubiquitinating Enzyme That Exhibits Prosurvival Function in the Cellular Response to DNA DamageMolecular and Cellular Biology, 2004
- p53's double life: transactivation-independent repression of homologous recombinationTrends in Genetics, 2004
- Rad51 overexpression promotes alternative double-strand break repair pathways and genome instabilityOncogene, 2004
- Overexpression of mammalian Rad51 does not stimulate tumorigenesis while a dominant-negative Rad51 affects centrosome fragmentation, ploidy and stimulates tumorigenesis, in p53-defective CHO cellsOncogene, 2003
- Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1Human Molecular Genetics, 2003
- Selective induction of cell cycle regulatory genes cdk1 (p34cdc2), cyclins a/b, and the tumor suppressor gene RB in transformed cells by okadaic acidJournal of Cellular Physiology, 1995
- Proliferation in non‐hodgkin's lymphomas as determined by immunohistochemical double staining for Ki‐67Hematological Oncology, 1992